Trial Profile
A Phase I Study of a p53MVA Vaccine in Combination With Gemcitabine in Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; MVA-p53 (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Pharmacodynamics
- 26 Apr 2018 Status changed from active, no longer recruiting to completed.
- 04 Jan 2018 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 18 Aug 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Aug 2018.